Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Short-term Investments: 2021-2025

Historic Short-term Investments for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Sep 2025 value amounting to $118.8 million.

  • Amylyx Pharmaceuticals' Short-term Investments fell 26.91% to $118.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.8 million, marking a year-over-year decrease of 26.91%. This contributed to the annual value of $99.1 million for FY2024, which is 50.73% down from last year.
  • Amylyx Pharmaceuticals' Short-term Investments amounted to $118.8 million in Q3 2025, which was down 3.20% from $122.7 million recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Short-term Investments registered a high of $284.4 million during Q4 2022, and its lowest value of $45.9 million during Q4 2021.
  • For the 3-year period, Amylyx Pharmaceuticals' Short-term Investments averaged around $167.9 million, with its median value being $162.6 million (2024).
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Short-term Investments soared by 519.28% in 2022 and then crashed by 50.73% in 2024.
  • Amylyx Pharmaceuticals' Short-term Investments (Quarterly) stood at $45.9 million in 2021, then soared by 519.28% to $284.4 million in 2022, then fell by 29.27% to $201.2 million in 2023, then plummeted by 50.73% to $99.1 million in 2024, then declined by 26.91% to $118.8 million in 2025.
  • Its Short-term Investments was $118.8 million in Q3 2025, compared to $122.7 million in Q2 2025 and $144.3 million in Q1 2025.